These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

640 related items for PubMed ID: 18024872

  • 1. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
    Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, Pierani P, Micalizzi C, Buffardi S, Basso G, Zanesco L, Rosolen A.
    J Clin Oncol; 2007 Nov 20; 25(33):5254-61. PubMed ID: 18024872
    [Abstract] [Full Text] [Related]

  • 2. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M, Jiang LM.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun 20; 10(3):333-6. PubMed ID: 18554462
    [Abstract] [Full Text] [Related]

  • 3. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
    Jiang H, Gu LJ, Xue HL, Tang JY, Chen J, Pan C, Chen J, Xu C, Dong L, Zhou M.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun 20; 10(3):290-4. PubMed ID: 18554450
    [Abstract] [Full Text] [Related]

  • 4. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 5. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
    Madzo J, Zuna J, Muzíková K, Kalinová M, Krejcí O, Hrusák O, Otová B, Starý J, Trka J.
    Cancer; 2003 Jan 01; 97(1):105-13. PubMed ID: 12491511
    [Abstract] [Full Text] [Related]

  • 6. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P, Mortuza FY, Hoffbrand AV, Foroni L.
    Haematologica; 2002 Nov 01; 87(11):1126-34. PubMed ID: 12414341
    [Abstract] [Full Text] [Related]

  • 7. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A, Wypych A, Rokicka-Milewska R, Siedlecki JA, Kulik J.
    Przegl Lek; 2004 Nov 01; 61 Suppl 2():62-6. PubMed ID: 15686049
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group.
    J Clin Oncol; 2009 Jan 20; 27(3):377-84. PubMed ID: 19064980
    [Abstract] [Full Text] [Related]

  • 9. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G.
    J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690
    [Abstract] [Full Text] [Related]

  • 10. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R, Mejstrikova E, Stary J, Trka J.
    Pediatr Blood Cancer; 2007 Jan 01; 48(1):93-100. PubMed ID: 16521130
    [Abstract] [Full Text] [Related]

  • 11. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
    Attarbaschi A, Mann G, Dworzak M, Trebo M, Urban C, Fink FM, Horcher E, Reiter A, Riehm H, Gadner H, Austrian Cooperative Study Group.
    Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):978-86. PubMed ID: 12635465
    [Abstract] [Full Text] [Related]

  • 12. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G.
    Leukemia; 2008 Dec 30; 22(12):2193-200. PubMed ID: 18754029
    [Abstract] [Full Text] [Related]

  • 13. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ, Gu LJ, Song DL, Jiang LM, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Wang YP, Chen J.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 30; 26(1):6-9. PubMed ID: 15946500
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group.
    Br J Haematol; 2009 Aug 30; 146(3):292-9. PubMed ID: 19500099
    [Abstract] [Full Text] [Related]

  • 15. A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia.
    Levett D, Middleton P, Cole M, Reid MM.
    Med Pediatr Oncol; 2001 Mar 30; 36(3):365-71. PubMed ID: 11241438
    [Abstract] [Full Text] [Related]

  • 16. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B, Avigad S, Luria D, Manor S, Reshef-Ronen T, Avrahami G, Yaniv I.
    Pediatr Blood Cancer; 2009 Jan 30; 52(1):20-5. PubMed ID: 19006253
    [Abstract] [Full Text] [Related]

  • 17. [Prognostic value of minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
    Tie LJ, Gu LJ, Chen J, Jiang LM, Dong L, Pan C, Ye H, Song DL, Xue HL, Tang JY, Wang YP, Chen J.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb 30; 27(2):120-3. PubMed ID: 16732969
    [Abstract] [Full Text] [Related]

  • 18. Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt's lymphomas by long-distance polymerase chain reaction for t(8;14)(q24;q32).
    Mussolin L, Basso K, Pillon M, D'Amore ES, Lombardi A, Luzzatto L, Zanesco L, Rosolen A.
    Leukemia; 2003 Mar 30; 17(3):585-9. PubMed ID: 12646948
    [Abstract] [Full Text] [Related]

  • 19. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Król M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A.
    Br J Haematol; 2008 Jun 30; 142(2):227-37. PubMed ID: 18492099
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G.
    J Clin Oncol; 2003 Dec 01; 21(23):4413-22. PubMed ID: 14645432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.